Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Outlook Therapeutics Inc (OTLK)

Outlook Therapeutics Inc (OTLK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,557
  • Shares Outstanding, K 64,114
  • Annual Sales, $ 1,410 K
  • Annual Income, $ -62,420 K
  • EBIT $ -73 M
  • EBITDA $ -73 M
  • 60-Month Beta 0.17
  • Price/Sales 23.89
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.50
  • Most Recent Earnings $-0.22 on 12/19/25
  • Next Earnings Date 02/13/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 220.13% (+12.61%)
  • Historical Volatility 266.24%
  • IV Percentile 55%
  • IV Rank 21.61%
  • IV High 630.48% on 04/07/25
  • IV Low 107.01% on 01/20/26
  • Expected Move (DTE 24) 0.0935 (18.73%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 32
  • Volume Avg (30-Day) 2,185
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 27,166
  • Open Int (30-Day) 47,756
  • Expected Range 0.4057 to 0.5927

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.17
  • Number of Estimates 3
  • High Estimate -0.09
  • Low Estimate -0.27
  • Prior Year -0.89
  • Growth Rate Est. (year over year) +80.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4811 +4.97%
on 01/27/26
2.0300 -75.12%
on 12/30/25
-1.3150 (-72.25%)
since 12/26/25
3-Month
0.4811 +4.97%
on 01/27/26
2.5375 -80.10%
on 12/17/25
-0.8350 (-62.31%)
since 10/27/25
52-Week
0.4811 +4.97%
on 01/27/26
3.3900 -85.10%
on 08/26/25
-1.3750 (-73.14%)
since 01/27/25

Most Recent Stories

More News
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.5004 (-1.46%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVAâ„¢ (bevacizumab-vikg) for the Treatment of Wet AMD

ISELIN, N.J., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.5004 (-1.46%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces New Employment Inducement Grants

ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.5004 (-1.46%)
OTLKW : 0.03 (-1.96%)
GDP in Canadian Spotlight Next Week

Monday U.S. Featured Earnings Bridgeline Digital Inc (NASDAQ: BLIN) (Q4) EPS ...

BLIN : 0.8271 (+0.40%)
OTLK : 0.5004 (-1.46%)
LMNR : 14.10 (-2.42%)
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.5004 (-1.46%)
OTLKW : 0.03 (-1.96%)
Micron Dominates Barchart's Top 100 with Killer Volume—Your Buy Signal?

In Monday’s trading, Micron Technology jumped 14 spots in Barchart’s Top 100 Stocks to Buy, into 36th position. Of the top 100, Micron’s price volume was the highest at 6.53 million, nearly four...

IREN : 59.67 (+13.96%)
OTLK : 0.5004 (-1.46%)
NVDA : 189.48 (+1.61%)
MU : 413.96 (+6.39%)
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

ISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.5004 (-1.46%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Prescription Drug User Fee Act (PDUFA) goal date of December 31, 2025 ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused...

OTLK : 0.5004 (-1.46%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

ISELIN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of...

OTLK : 0.5004 (-1.46%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Provides Update on Type A Meeting with FDA

ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.   (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment...

OTLK : 0.5004 (-1.46%)
OTLKW : 0.03 (-1.96%)

Business Summary

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as...

See More

Key Turning Points

3rd Resistance Point 0.5619
2nd Resistance Point 0.5443
1st Resistance Point 0.5261
Last Price 0.5004
1st Support Level 0.4903
2nd Support Level 0.4727
3rd Support Level 0.4545

See More

52-Week High 3.3900
Fibonacci 61.8% 2.2788
Fibonacci 50% 1.9356
Fibonacci 38.2% 1.5923
Last Price 0.5004
52-Week Low 0.4811

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar